Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Hexamidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.96 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.96 |
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.96 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.96 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.96 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.96 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.96 |
| ▸ | GRIN2A known ✓ | Q12879 | 1/20 | 0.96 |
| ▸ | PRMT1 | Q99873 | 3/20 | 0.96 |
| ▸ | F2 | P00734 | 2/20 | 0.96 |
| ▸ | ST14 | Q9Y5Y6 | 2/20 | 0.96 |
| ▸ | TMPRSS2 | O15393 | 2/20 | 0.96 |
| ▸ | PLAU | P00749 | 1/20 | 0.96 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.96 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.96 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.96 |
| ▸ | PTP4A3 | O75365 | 1/20 | 0.96 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.96 |
| ▸ | F10 | P00742 | 1/20 | 0.96 |
| ▸ | PLG | P00747 | 1/20 | 0.96 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hexamidine SCHEMBL144738 | 0.98 | PRMT1 (1.00) | PRMT1F2ST14TMPRSS2PLAU | |
| SCHEMBL14599631 | 0.98 | PRMT1 (1.00) | PRMT1F2ST14TMPRSS2PLAU | |
| SCHEMBL14599628 | 0.98 | PRMT1 (1.00) | PRMT1F2ST14TMPRSS2PLAU | |
| SCHEMBL14599639 | 0.98 | PRMT1 (1.00) | PRMT1F2ST14TMPRSS2PLAU | |
| Pentamidine SCHEMBL3329 | 0.98 | PRMT1 (1.00) | PRMT1F2ST14TMPRSS2PLAU | |
| Heptamidine SCHEMBL14599630 | 0.98 | PRMT1 (1.00) | PRMT1F2ST14TMPRSS2PLAU | |
| Pentamidine SCHEMBL3227 | 0.96 | PRSS1 (1.00) | PRMT1F2ST14TMPRSS2PLAU | |
| Pentamidine SCHEMBL7060561 | 0.96 | PRSS1 (1.00) | PRMT1F2ST14TMPRSS2PLAU | |
| Hexamidine SCHEMBL3629982 | 0.96 | PRSS1 (1.00) | PRMT1F2ST14TMPRSS2PLAU | |
| Hexamidine SCHEMBL18701066 | 0.96 | PRMT1 (0.96) | PRMT1F2ST14TMPRSS2PLAU |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1855700-B1 | USE OF NEURONAL PRECURSOR CELLS FOR TREATMENT OF CENTRAL NERVOUS SYSTEM LESIONS | SANBIO INC (US) | 2013-10-30 | — | — | EP | disclosed |
| US-8092792-B2 | Use of materials for treatment of central nervous system lesions | SANBIO, INC. (US) | 2012-01-10 | — | — | US | disclosed |
| US-20100034790-A1 | Use of materials for treatment of central nervous system lesions | SANBIO, INC. | 2010-02-11 | — | — | US | disclosed |
| EP-1855700-A2 | USE OF NEURONAL PRECURSOR CELLS FOR TREATMENT OF CENTRAL NERVOUS SYSTEM LESIONS | SanBio, Inc. (US) | 2007-11-21 | — | — | EP | disclosed |
| US-20060216276-A1 | Use of materials for treatment of central nervous system lesions | SANBIO, INC. | 2006-09-28 | — | — | US | disclosed |
| WO-2006096640-A2 | USE OF NEURONAL PRECURSOR CELLS FOR TREATMENT OF CENTRAL NERVOUS SYSTEM LESIONS | SANBIO INC. (US) | 2006-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060216276-A1 | Use of materials for treatment of central nervous system lesions | NES, DCX, NEFM | CHRM2 1212/4885ADRA2A 4284/4885ACHE 106/4885 |
| US-20100034790-A1 | Use of materials for treatment of central nervous system lesions | NES, DCX, NEFM | CHRM2 1212/4885ADRA2A 4284/4885ACHE 106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.